|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MSL3 |
Gene summary for MSL3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MSL3 | Gene ID | 10943 |
| Gene name | MSL complex subunit 3 | |
| Gene Alias | MRSXBA | |
| Cytomap | Xp22.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q8N5Y2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10943 | MSL3 | LZE4T | Human | Esophagus | ESCC | 2.21e-05 | 2.21e-01 | 0.0811 |
| 10943 | MSL3 | LZE8T | Human | Esophagus | ESCC | 3.13e-05 | 2.29e-01 | 0.067 |
| 10943 | MSL3 | LZE20T | Human | Esophagus | ESCC | 1.33e-02 | 5.31e-02 | 0.0662 |
| 10943 | MSL3 | LZE22T | Human | Esophagus | ESCC | 7.35e-04 | 2.02e-01 | 0.068 |
| 10943 | MSL3 | LZE24T | Human | Esophagus | ESCC | 2.16e-11 | 1.75e-01 | 0.0596 |
| 10943 | MSL3 | LZE6T | Human | Esophagus | ESCC | 7.30e-04 | 2.33e-01 | 0.0845 |
| 10943 | MSL3 | P1T-E | Human | Esophagus | ESCC | 1.08e-02 | 1.07e-01 | 0.0875 |
| 10943 | MSL3 | P2T-E | Human | Esophagus | ESCC | 1.00e-18 | 3.41e-01 | 0.1177 |
| 10943 | MSL3 | P4T-E | Human | Esophagus | ESCC | 7.00e-14 | 2.38e-01 | 0.1323 |
| 10943 | MSL3 | P5T-E | Human | Esophagus | ESCC | 2.63e-11 | 1.98e-01 | 0.1327 |
| 10943 | MSL3 | P8T-E | Human | Esophagus | ESCC | 4.17e-16 | 3.56e-01 | 0.0889 |
| 10943 | MSL3 | P10T-E | Human | Esophagus | ESCC | 1.07e-11 | 1.98e-01 | 0.116 |
| 10943 | MSL3 | P11T-E | Human | Esophagus | ESCC | 1.35e-02 | 2.72e-01 | 0.1426 |
| 10943 | MSL3 | P12T-E | Human | Esophagus | ESCC | 1.08e-10 | 1.56e-01 | 0.1122 |
| 10943 | MSL3 | P15T-E | Human | Esophagus | ESCC | 4.94e-08 | 1.64e-01 | 0.1149 |
| 10943 | MSL3 | P16T-E | Human | Esophagus | ESCC | 6.59e-19 | 2.90e-01 | 0.1153 |
| 10943 | MSL3 | P17T-E | Human | Esophagus | ESCC | 2.69e-05 | 2.07e-01 | 0.1278 |
| 10943 | MSL3 | P19T-E | Human | Esophagus | ESCC | 1.38e-04 | 4.41e-01 | 0.1662 |
| 10943 | MSL3 | P20T-E | Human | Esophagus | ESCC | 1.98e-10 | 2.64e-01 | 0.1124 |
| 10943 | MSL3 | P21T-E | Human | Esophagus | ESCC | 8.68e-11 | 1.83e-01 | 0.1617 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001657015 | Esophagus | ESCC | histone modification | 323/8552 | 463/18723 | 2.61e-26 | 7.88e-24 | 323 |
| GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
| GO:001839413 | Esophagus | ESCC | peptidyl-lysine acetylation | 123/8552 | 169/18723 | 6.58e-13 | 2.94e-11 | 123 |
| GO:004354313 | Esophagus | ESCC | protein acylation | 165/8552 | 243/18723 | 1.69e-12 | 7.14e-11 | 165 |
| GO:000647313 | Esophagus | ESCC | protein acetylation | 140/8552 | 201/18723 | 4.37e-12 | 1.69e-10 | 140 |
| GO:001839313 | Esophagus | ESCC | internal peptidyl-lysine acetylation | 114/8552 | 158/18723 | 1.16e-11 | 4.24e-10 | 114 |
| GO:000647513 | Esophagus | ESCC | internal protein amino acid acetylation | 115/8552 | 160/18723 | 1.43e-11 | 5.08e-10 | 115 |
| GO:00165735 | Esophagus | ESCC | histone acetylation | 110/8552 | 152/18723 | 1.95e-11 | 6.81e-10 | 110 |
| GO:004396712 | Esophagus | ESCC | histone H4 acetylation | 53/8552 | 67/18723 | 2.11e-08 | 4.03e-07 | 53 |
| GO:00356015 | Esophagus | ESCC | protein deacylation | 79/8552 | 112/18723 | 8.30e-08 | 1.42e-06 | 79 |
| GO:00987325 | Esophagus | ESCC | macromolecule deacylation | 80/8552 | 116/18723 | 3.19e-07 | 4.50e-06 | 80 |
| GO:00165754 | Esophagus | ESCC | histone deacetylation | 60/8552 | 82/18723 | 3.85e-07 | 5.32e-06 | 60 |
| GO:00064765 | Esophagus | ESCC | protein deacetylation | 70/8552 | 101/18723 | 1.29e-06 | 1.58e-05 | 70 |
| GO:00439682 | Esophagus | ESCC | histone H2A acetylation | 15/8552 | 17/18723 | 3.48e-04 | 2.03e-03 | 15 |
| GO:004398411 | Esophagus | ESCC | histone H4-K16 acetylation | 16/8552 | 20/18723 | 1.85e-03 | 8.40e-03 | 16 |
| GO:00064731 | Liver | Cirrhotic | protein acetylation | 84/4634 | 201/18723 | 7.50e-08 | 2.25e-06 | 84 |
| GO:00183941 | Liver | Cirrhotic | peptidyl-lysine acetylation | 73/4634 | 169/18723 | 1.08e-07 | 3.07e-06 | 73 |
| GO:00435431 | Liver | Cirrhotic | protein acylation | 95/4634 | 243/18723 | 4.73e-07 | 1.07e-05 | 95 |
| GO:00182051 | Liver | Cirrhotic | peptidyl-lysine modification | 134/4634 | 376/18723 | 1.29e-06 | 2.59e-05 | 134 |
| GO:00064751 | Liver | Cirrhotic | internal protein amino acid acetylation | 65/4634 | 160/18723 | 6.66e-06 | 1.04e-04 | 65 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MSL3 | SNV | Missense_Mutation | c.1012N>T | p.Arg338Cys | p.R338C | Q8N5Y2 | protein_coding | tolerated(0.06) | probably_damaging(0.98) | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| MSL3 | SNV | Missense_Mutation | novel | c.21N>C | p.Met7Ile | p.M7I | Q8N5Y2 | protein_coding | tolerated(0.65) | benign(0.003) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| MSL3 | SNV | Missense_Mutation | c.223N>A | p.Asp75Asn | p.D75N | Q8N5Y2 | protein_coding | tolerated(0.23) | probably_damaging(0.984) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| MSL3 | SNV | Missense_Mutation | c.1279N>A | p.Glu427Lys | p.E427K | Q8N5Y2 | protein_coding | tolerated(0.08) | probably_damaging(0.995) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| MSL3 | SNV | Missense_Mutation | c.394N>C | p.Ser132Pro | p.S132P | Q8N5Y2 | protein_coding | deleterious(0.02) | benign(0.088) | TCGA-GM-A2DH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR | |
| MSL3 | insertion | Frame_Shift_Ins | novel | c.951_952insGTAGTTACGTTTCAACGAGGTGGTAGGGTATTCTTGT | p.Ser318ValfsTer26 | p.S318Vfs*26 | Q8N5Y2 | protein_coding | TCGA-A8-A08T-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| MSL3 | SNV | Missense_Mutation | novel | c.815N>C | p.Val272Ala | p.V272A | Q8N5Y2 | protein_coding | deleterious(0.01) | benign(0.089) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MSL3 | SNV | Missense_Mutation | rs372729360 | c.1552N>T | p.Arg518Trp | p.R518W | Q8N5Y2 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.556) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MSL3 | SNV | Missense_Mutation | novel | c.830A>G | p.Tyr277Cys | p.Y277C | Q8N5Y2 | protein_coding | tolerated(0.19) | benign(0.018) | TCGA-LP-A4AW-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| MSL3 | SNV | Missense_Mutation | c.1494N>G | p.Phe498Leu | p.F498L | Q8N5Y2 | protein_coding | deleterious(0.03) | probably_damaging(0.982) | TCGA-UC-A7PG-06 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | PD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |